Psilocybin
Cybin Lands Key U.S. Patent for DMT Compounds
Preliminary DMT therapy data will guide the decision to initiate a phase 2 trial in the U.S. in early 2024.
The post Cybin Lands Key U.S. Patent for DMT…
Cybin Inc. (NYSE: CYBN) (NEO: CYBN) successfully obtained a U.S. patent for the compounds it uses in pre-clinical deuterated tryptamine research. The patent, No. 11,746,088, is valid until 2041.
Preliminary data from the trials on deuterated dimethyltryptamine (dDMT) are anticipated by the end of 2023. The data will guide the decision to initiate a phase 2 trial in the U.S. in early 2024, focusing on the potential therapeutic benefits of dDMT.
In a statement, Cybin CEO Doug Drysdale touted the company’s plans to merge with short-duration psychedelic therapy developer, Small Pharma.
“The strong synergy of our collective intellectual property provides an unparalleled opportunity to develop novel, differentiated therapeutics for patients in need of improved treatment options,” he said.
“Looking towards the next chapter for the combined company, this new composition of matter patent will have an important role in protecting the continued advancement of our development pipeline.”
Additionally, the company said it aims to disclose results for its study on CYB003, a synthetic form of psilocybin, for major depressive disorder and the CYB004-E study in the same timeframe.
Previous tests of CYB003, involving doses up to 12 milligrams, have reportedly shown it to be well-tolerated, with the company noting no serious side effects in their recent patient testing.
After these data releases, the company intends to present its research to the U.S. Food and Drug Administration. A phase 3 study of CYB003 is in the planning stages for a potential 2024 start.
The post Cybin Lands Key U.S. Patent for DMT Compounds appeared first on Green Market Report.
psilocybin dmt dimethyltryptamine psychedelic therapeutics therapy major depressive disorder depressive disorder cybin small pharma research
-
Psychedelics1 week agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week agoPsilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment